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Abstract
 
The cytokines interleukin (IL)-2, IL-4, IL-6, IL-7, and IL-15 have all previously been shown
to inhibit resting T cell death in vitro. We have found a difference in the response of T cells to
IL-6, depending on the activation status of the cells. IL-6 inhibited the death of naive T cells,
but had no effect on the death of either superantigen-activated T cells, or T cells bearing mem-
ory markers. This was true even when the resting and activated T cells were isolated from the
same animal; thus, the determining factor for IL-6 insensitivity was the activation status or acti-
vation history of the cell, and not the milieu in the animal from which the cells were isolated.
Activated T cells expressed lower levels of IL-6 receptors on their surfaces, yet there were suf-
ficient levels of receptors for signaling, as we observed similar levels of signal transducer and ac-
 
tivator of transcription (Stat)3 phosphorylation in resting and activated T cells treated with IL-6.
However, there was profound inhibition of IL-6–induced Stat1 phosphorylation in activated T
cells compared with resting T cells. These data suggest that there is activation-induced inhibi-
tion of IL-6 receptor signaling in T cells. This inhibition appears to be specific for some but not
all of the IL-6–mediated signaling cascades in these cells.
Key words: cytokine • survival • memory • death • signal transducer and activator of 
transcription 3
 
Introduction
 
Mouse T cells survive in vitro for only a few days, whereas
the life span of resting mouse T cells in vivo is in the order
of weeks to months (1–5). Therefore, T cells appear to
have a default death mechanism, and sustained signaling
from survival factors in vivo may promote the prolonged
life span observed in animals. The death rate of activated T
cells is very different from that of resting T cells (6–10). Af-
ter activation, T cells die rapidly in vivo or in vitro by a
process referred to as activation-induced cell death. Many
researchers have focused on the mechanisms of the en-
hanced death rates of activated T cells, and several processes
that lead to their death have now been described (11–15).
 
In our own experiments on this subject, we have used a
system in which the death in culture of either resting or in
vivo–activated T cells is used as a tool to screen cytokines and
growth factors for their ability to provide survival signals to T
cells (16–19). We used bacterial superantigens to activate eas-
ily trackable populations of T cells bearing particular TCR
 
V
 
b
 
s in normal mice or to activate the entire T cell population
in TCR transgenic mice. We then followed the survival of
these T cells in tissue culture in the presence or absence of
various soluble or plate-bound factors. Although both resting
and superantigen-activated T cells died in vitro, there was a
substantial increase in the rate of death of activated T cells in
vitro compared with the rate of death of resting T cells.
Experiments on the processes that led to the accelerated
death of these activated T cells showed that, unexpectedly,
the cells were not dying in vivo or in vitro because of engage-
ment of Fas or TNF receptors and caspase activation. Instead,
the cells were dying because they contained increased levels
of reactive oxygen species which, directly or indirectly, led to
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the destruction of the cells (20). In unpublished work, similar
results have been obtained for T cells stimulated with con-
ventional antigens, so this caspase-independent death is not
restricted to T cells activated with superantigens.
The search for the factors that regulate the survival of rest-
ing and activated T cells has implicated several mechanisms.
Engagement of their TCRs by MHC has been reported to
be required for the prolonged survival of resting T cells in
vivo (21, 22). Engagements of CD28, other cell surface mol-
ecules, or the cytokines that bind the common 
 
g
 
 chain cy-
tokine receptor family appear to be capable of blocking acti-
vation-induced T cell death in several systems (23–26).
Using superantigen-activated T cells, we identified sev-
eral cytokines that inhibited the death of T cells. These
included members of the IL-2 family of cytokines, IL-2,
IL-4, IL-7, and IL-15 (17, 19). IL-4 and IL-7 were more
efficient inhibitors of resting T cell death than IL-2 and
IL-15, probably because resting T cells do not bear high
affinity receptors for these latter cytokines. Of these cyto-
kines, IL-2 is known to make T cells in vivo more sus-
ceptible to activation-induced cell death (27). The fact
that this cytokine prevents the death of activated T cells
in vitro suggests that activated T cells may be dying for
different reasons in animals than in tissue culture dishes.
However, we do not believe this is so because we do not
think that IL-2 is the effector of either death or survival of
the activated T cells in animals. IL-2 is not being made in
large quantities at the time the activated cells are about to
die, and the activated T cells do not contain the high lev-
els of 
 
Bcl2
 
 characteristic of IL-2 family exposure (28).
We previously showed that the proinflammatory cytokine
IL-6 prevented the death of resting T cells (16); however,
we did not then study the effect of IL-6 on activated or
memory T cells. Since we previously showed that an LPS-
induced proinflammatory environment could provide rescue
of activated T cells from in vivo deletion, it was of interest to
us to determine if IL-6 could rescue activated T cells in
vitro. IL-6 was singled out as a good candidate because none
of the other proinflammatory cytokines we tested had been
capable of rescuing the resting T cells.
In this paper, we report that IL-6 had no effect on the
survival of T cells, either activated in vivo or bearing
memory markers. Bystander resting T cells from mice
containing activated T cells could be rescued from death
by IL-6; therefore, T cell activation appeared to be the
determining factor for IL-6 insensitivity. We found only a
moderate loss of IL-6 receptors after in vivo T cell activa-
tion with superantigen. We show that the loss of IL-6
sensitivity in the activated cells was not due to a complete
lack of IL-6 receptor signaling, as IL-6 induced phosphor-
ylation of signal transducer and activator of transcription
(Stat)
 
1
 
 3 in the activated cells. There was a loss of Stat1
phosphorylation in response to IL-6 in the activated T
 
cells; thus, T cell activation appears to elicit an inhibitor
specific for Stat1 signaling. 
In sum, these results show that activation has several ef-
fects on T cells. Activation reduces T cells’ ability to respond
to a survival signal, IL-6, supplied by activation of innate im-
munity while increasing their ability to respond to signals
(provided in part by activated T cells themselves) that in-
clude some members of the IL-2 family of cytokines.
 
Materials and Methods
 
Reagents and Mice.
 
Recombinant mouse IL-2, IL-4, IL-6, and
IL-7 were purchased from R&D Systems. FITC- and PE-coupled
antibodies against TCR V
 
b
 
4, V
 
b
 
5, V
 
b
 
6, V
 
b
 
8, V
 
b
 
11, and V
 
b
 
14,
biotinylated antibodies against IL-6 receptor 
 
a
 
 chain, and biotiny-
lated isotype control antibodies (rat IgG2b
 
k
 
) were purchased from
PharMingen. B220-specific FITC- and Cychrome
 
®
 
-coupled anti-
bodies were purchased from PharMingen. The secondary staining
reagent streptavidin-Cychrome
 
®
 
 was also purchased from Phar-
Mingen. The anti-TCR V
 
b
 
3 mAb KJ25a, the anti-TCR mAb
H57-597 (H597), and the anti–I-A
 
b
 
 mAb Y3P were purified from
hybridoma supernatants and FITC coupled in our laboratory. The
phospho-Stat3 (Tyr
 
705
 
), phospho-Stat3 (Ser
 
727
 
), and phospho-Stat1
(Tyr
 
701
 
) rabbit polyclonal anti–mouse antibodies were from New
England Biolabs. The rabbit polyclonal anti–mouse Stat3 and Stat1
antibodies were from Santa Cruz Biotechnology. The peroxidase-
labeled goat anti–rabbit IgG antibody was from Kirkegaard & Perry
Laboratories. FITC–annexin V was purchased from R&D Sys-
tems. Propidium iodide (PI) was from Sigma Chemical Co. The
protease and phosphatase inhibitors PMSF, Na
 
3
 
VO
 
4
 
, NaF, aproti-
nin, 
 
a
 
1 antitrypsin, and leupeptin were from Sigma Chemical Co.
C57BL/10SnJ (C57BL/10), BALB/cByJ (BALB/c), and B10.BR/
SgSnJ (B10.BR) female mice were purchased from The Jackson
Laboratory. B10.BR mice transgenic for the V
 
b
 
3
 
1
 
 TCR, AD10,
were bred from mice provided by Dr. S. Hedrick (University of
California, San Diego, CA). FBS was purchased from Intergen or
from Summit Biotechnology. MEM culture medium was purchased
from GIBCO BRL. Staphylococcal enterotoxin A (SEA) and SEB
were purchased from either Sigma Chemical Co. or ToxinTech.
 
T Cell Activation.
 
Cells were activated in vivo with bacterial
superantigens. We have found that mouse strain and superantigen
(SEB versus SEA) are irrelevant in our in vitro system of T cell
death and survival. B10.BR female mice were injected either in-
traperitoneally or intravenously with the amount of SEA indicated
in the figure legends. C57BL/10 female mice were injected intra-
venously or intraperitoneally with 150 
 
m
 
g SEB. T cells were iso-
lated after the times indicated in the figure legends.
 
T Cell Isolation and Culture.
 
LNs from B10.BR or C57BL/10
mice were removed and pressed through cell strainers (Falcon;
Becton Dickinson) to produce single cell suspensions. The cell
suspensions were enriched for T cells by passage through nylon
wool columns (29). Cells were suspended in MEM supplemented
with 10% FBS and nonessential amino acids (CTM) and plated in
96-well plates (Falcon; Becton Dickinson) at the densities indi-
cated in the figure legends. Cells were cultured in the presence or
absence of the indicated cytokines and/or inhibitors at a final vol-
ume of 200 
 
m
 
l per well.
 
Isolation and Culture of Memory versus Naive T Cells.
 
Spleens were
harvested from 6-mo-old BALB/c female mice. We used BALB/c
mice in these experiments because we needed mice that contained
a reasonable number of memory cells and BALB/c mice of this
age had such cells and were available. The spleens were passed
 
1
 
Abbreviations used in this paper:
 
 HPRT, hypoxanthine ribosyltransferase;
Jak, Janus kinase; PI, propidium iodide; PIAS, protein inhibitor of activated
Stat; SEA and SEB, staphylococcal enterotoxin A and B; SOCS, suppressor
of cytokine signaling; Stat, signal transducer and activator of transcription. 
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through cell strainers, and cells were enriched for T cells by pas-
sage through nylon wool columns. The cells were then stained with
anti-B220–FITC, anti–MAC-1–FITC, anti-CD44–Cychrome,
and either anti-CD45RB–PE or anti-CD62L–PE. The cells were
sorted using a MoFlo™ cell sorter from Cytomation. The cells
were gated on live cells and all FITC
 
1
 
 cells were dumped. The
remaining cells were sorted into naive (CD44
 
low
 
CD45RB
 
high
 
or CD44
 
low
 
CD62L
 
high
 
) and memory (CD44
 
high
 
CD45RB
 
low
 
 or
CD44
 
high
 
CD62L
 
low
 
) populations. The cells were cultured at 37
 
8
 
C
for 30 h at 10
 
5
 
 cells per well in CTM containing heat-inactivated
FBS and the cytokines indicated in the figures.
 
Cell Death Analysis.
 
Immediately after isolation from the mouse
or after in vitro culture under various conditions, cells were ana-
lyzed for death by PI exclusion or FITC–annexin V binding. In
the PI exclusion assays, the cells were first stained on ice with
FITC-coupled anti-TCR antibodies, washed, and then incubated
on ice with 0.5 
 
m
 
g/ml PI for at least 15 min before analysis. In the
FITC–annexin V assays, cells were stained with FITC–annexin V
in annexin V binding buffer (BSS supplemented with 2.5 mM
CaCl
 
2
 
) at room temperature for 15 min. The cells were then
washed with cold binding buffer and immediately put on ice until
analyzed. Flow cytometry analysis was performed with a Becton
Dickinson FACScan™ instrument (Becton Dickinson). Data were
analyzed using either PC Lysis II™ software (Becton Dickinson)
or CELLQuest™ software (Becton Dickinson).
 
IL-6 Receptor Staining.
 
T cells were isolated from either un-
treated mice or mice injected with superantigen for the lengths of
time indicated in the figure legends. Immediately after isolation
from LNs, the T cells were incubated on ice with either biotin-
coupled anti–IL-6 receptor 
 
a
 
 chain mAb or a biotinylated iso-
type-matched rat IgG2b
 
k
 
 control antibody. The cells were washed
twice and then incubated on ice with streptavidin-Cychrome.
 
Western Blot Analysis of Stat Phosphorylation.
 
T cells were iso-
lated as described above from LNs of C57BL/10 female mice
treated with 150 
 
m
 
g SEB for 2 d (phospho-Stat3 [Ser
 
727
 
] blot,
phospho-Stat1 [Tyr
 
701
 
] blot) or 3 d (phospho-Stat3 [Tyr
 
705
 
] blot).
The cells were sorted into resting and activated T cell populations
using a MoFlo™ cell sorter. Only live gated cells were sorted and
the cells were stained with anti-B220–Cy-chrome to dump resid-
ual B cells. In the phospho-Stat3 (Ser
 
727
 
) assay, the cells were
stained with anti-V
 
b
 
5.x–PE to label resting T cells and anti-
V
 
b
 
8.x–FITC to label activated T cells. In the phospho-Stat3
(Tyr
 
705
 
) assay, the cells were stained with a combination of FITC-
coupled antibodies against V
 
b
 
4, V
 
b
 
6, V
 
b
 
11, and V
 
b
 
14 to label
resting T cells and anti-V
 
b
 
8.1,2–PE to label activated T cells. In
the phospho-Stat1 (Tyr
 
701
 
) assays, the LN cells from SEB-treated
C57BL/10 mice were stained with FITC-coupled anti–I-A
 
b
 
 mAb
Y3P instead of B220 to gate out APCs and costained with anti-
TCR V
 
b
 
8.x mAb F23.1 to sort out activated T cells. Resting T
cells were sorted from untreated C57BL/10 LNs using FITC-
coupled Y3P and anti-TCR mAb H597.
After sorting, the cells were pelleted once and resuspended into
serum-free medium. The cells were incubated at 37
 
8
 
C for 20 min
in the presence of medium alone or medium plus IL-6. Cells were
pelleted and lysed on ice for 15 min in lysis buffer containing 1%
NP-40, 10 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM
PMSF, 2 mM Na
 
3
 
VO
 
4
 
, 10 mM NaF, 1 
 
m
 
g/ml aprotinin, 1 
 
m
 
g/ml
 
a
 
1 antitrypsin, and 1 
 
m
 
g/ml leupeptin. The lysates were then cen-
trifuged at 4
 
8
 
C for 15 min, and supernatants were removed and
immediately added to 4
 
3
 
 SDS sample buffer containing 
 
b
 
-ME.
The lysates were boiled for 5 min and stored at 
 
2
 
80
 
8
 
C.
Lysates were run in 8% polyacrylamide gels. The gels were
transferred onto Immobilon-P™ polyvinylidene difluoride mem-
 
branes (Millipore) using a Trans-Blot SD Semi-Dry electro-
phoretic transfer cell from Bio-Rad. Membranes were blocked at
room temperature for 1–2 h with BLOTTO (5% milk and 1%
FBS in Tris-buffered saline [TBS] plus 0.05% Tween-20). Mem-
branes were washed with TBS-T (TBS plus 0.05% Tween-20)
and incubated at 4
 
8
 
C overnight with TBS-T containing 5% BSA
and a 1:1,000 dilution of the phospho-Stat antibodies. The blots
were washed with TBS-T and incubated for 45 min at room tem-
perature with BLOTTO containing a 1:10,000 dilution of the
peroxidase-labeled goat anti–rabbit IgG antibody. Membranes
were washed with TBS-T and developed for 1 min with ECL™
reagent (Amersham Pharmacia Biotech). Blots were visualized us-
ing Hyperfilm™-ECL™ (Amersham Pharmacia Biotech) and a
Fuji RGII x-ray film processor.
The phospho-Stat blots were then stripped for 30 min at 60
 
8
 
C
using a stripping buffer that contained 100 mM 
 
b
 
-ME, 2% SDS,
and 62.5 mM Tris-HCl, pH 6.7. The blots were washed with
TBS-T and blocked with BLOTTO. The membranes were then
probed for total Stat1 or Stat3 using the protocol described above.
 
Results
 
Activated T Cells Die More Rapidly In Vitro Than Resting T
Cells.
 
To assess the effects of cytokines on the survival of
resting or activated T cells, we used a system in which T
cells were isolated from either normal mice or mice that had
been treated 2–3 d previously with a superantigen (either
SEA, which targets T cells bearing V
 
b
 
3, or SEB, which tar-
gets T cells bearing V
 
b
 
8s). These cells were cultured under
various conditions and then stained with anti-V
 
b
 
 antibod-
ies. PI was used as a costain to measure cell permeability and
death. As shown in Fig. 1, V
 
b
 
3
 
1
 
 T cells isolated from an
untreated B10.BR mouse were 10.5% dead at the start of
the assay compared with 36.8% after 26 h in culture. The
V
 
b
 
3
 
1
 
 T cells isolated from a SEA-treated B10.BR mouse
were 25.4% dead at the start of the assay and showed accel-
erated death compared with the resting cells, with 94.4%
dead after 26 h in culture. The increase in dead cells seen at
the start of culture in the SEA-activated population corre-
lated with the in vivo deletion of target V
 
b
 
3
 
1
 
 cells that has
been previously shown to occur after day 2 of SEA activa-
tion (7). Fig. 1 illustrates both the in vivo expansion of the
V
 
b
 
3
 
1
 
 cells by SEA treatment (3.8% in the untreated vs.
13.0% in the SEA-treated) and the enhanced death that oc-
curred in the SEA-activated T cells. Similar results have also
been obtained using PI-saponin (DNA degradation) and
FITC–annexin V methods to analyze death in this system
and with V
 
b
 
8
 
1
 
 T cells activated with SEB.
 
IL-6 Inhibits In Vitro Death of Resting but Not Activated T
Cells.
 
To analyze the effect of IL-6 on superantigen-acti-
vated or resting T cells, we incubated T cells from either su-
perantigen-treated or untreated B10.BR or C57BL/10 mice
in the presence or absence of IL-6 (Table I). We found that
IL-6 rescued resting T cells from death but did not inhibit the
death of activated T cells. Table I shows six independent ex-
periments that were completed to compare the effect of IL-6
on resting cells from untreated mice with its effect on resting
and activated T cells from superantigen-treated mice. In all
the experiments, the resting cell death was inhibited by IL-6. 
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Inhibition of death averaged 39.5% for resting cells isolated
from untreated mice, and 30.4% for resting cells isolated from
superantigen-treated mice. The activated T cells, isolated
from superantigen-treated mice, bearing the target TCR V
 
b
 
(V
 
b3 for SEA, Vb8 for SEB) were unaffected by IL-6 in
these assays. Since the nontarget (resting) T cells from the
superantigen-treated mice were rescued by IL-6, the insensi-
tivity to IL-6 in the activated T cells could not have been
solely mediated by cytokines expressed during activation.
Therefore, these data suggest that signaling through the TCR
rather than the cytokine milieu in the mouse was the deter-
mining factor for loss of IL-6 sensitivity in these survival assays.
Loss of IL-6 sensitivity was not unique to T cells activated
in vivo by superantigens. Insensitivity to IL-6 could also be
induced in vitro. For example, T cells activated in vitro with
PMA and ionomycin were completely insensitive to IL-6
rescue, whereas their death was prevented by IL-2, IL-4, or
IL-7 (data not shown). Thus, induction of insensitivity to IL-6
did not depend on a nonlymphoid phenomenon present in
animals but not present in tissue culture.
Sensitivity to Various Cytokines for Survival Depends on Activa-
tion of the T Cells. Although the doses of IL-6 used in Table
I were sufficient for death inhibition of resting T cells (16), it
is possible that a greater concentration of IL-6 was required
for survival of activated T cells. This question is addressed in
Fig. 2, in which we assessed the dose–responses of resting and
activated T cells to IL-6, IL-2, IL-4, and IL-7. As previously
reported, IL-2 was effective at mediating survival of resting T
cells only at higher concentrations (50 ng/ml or greater),
whereas IL-4 and IL-7 effectively inhibited death of resting T
cells at amounts as low as 100–500 pg/ml. Low concentra-
tions of IL-6 also inhibited resting T cell death; however, the
percentage of T cells rescued was lower than that rescued by
IL-4 and IL-7, suggesting that there was a subpopulation of
resting T cells that was IL-6 insensitive before activation.
IL-6 had no rescuing effect on activated T cells even at the
highest concentrations added (0.5 mg/ml; Fig. 2 B). On the
other hand the cytokines IL-2, IL-4, and IL-7 were very ef-
Figure 1. Death of resting and activated T cells in tissue culture. LN
T cells isolated from an untreated B10.BR mouse (A and B) or a
B10.BR mouse treated with SEA (C and D) were analyzed for death at
the start of culture (A and C) and after 26 h in tissue culture (B and D).
Cells were stained with FITC–anti-TCR Vb3 and PI as described in
Materials and Methods.
Table I. IL-6 Inhibits the Death of Resting but Not Activated T Cells
Superantigen 
mouse strain
Time in 
culture
IL-6 
treatment
Resting T 
cells from 
untreated 
mice
Resting T cells 
from 
superantigen-
treated mice
Activated T cells 
from superantigen-
treated mice
h % Dead % Dead % Dead
Exp. 1 SEA (3 d) 24 2 40.3 51.7 94.3
B10.BR 1 19.3 31.6 95.3
Exp. 2 SEA (2 d) 24 2 46.7 53.7 91.2
B10.BR 1 31.5 39.7 94.9
Exp. 3 SEA (2 d) 34 2 53.3 53.5 87.4
B10.BR 1 32.7 39.8 87.8
Exp. 4 SEA (3 d) 26 2 36.8 41.9 94.7
B10.BR 1 21.5 26.6 95.8
Exp. 5 SEA (2 d) 29 2 67.2 50.9 87.6
B10.BR 1 45.6 33.5 93.8
Exp. 6 SEB (2 d) 27 2 51.6 ND 89.4
C57BL/10 1 30.9 ND 85.6
T cells were isolated from mouse LNs and cultured in vitro for the indicated times in the presence or absence of IL-6. Cell death was analyzed by PI
exclusion in experiments (Exp.) 1, 3, 4, and 6. Cell death was analyzed by annexin V staining in experiments 2 and 5. The dose of IL-6 was either
10 or 100 ng/ml in each experiment.919 Teague et al.
fective at inhibiting the death of the activated T cells. These
data suggest that the IL-6 insensitivity shown in Table I was
not due simply to a requirement for a higher concentration
of IL-6 by the activated T cells. These data also illustrate the
different regulation of effects of the various cytokines de-
pending on the activation state of the target cell. A higher
dose of IL-2 was required to rescue resting cells than to res-
cue activated T cells. This is presumably due to the upregu-
lation of high affinity IL-2 receptors on activated T cells.
Resting T Cells Bearing Memory Markers Are Also Insensitive
to IL-6 Rescue. Since there was a subpopulation of resting T
cells that was unresponsive to IL-6 (shown in Fig. 2), we were
interested in determining if this subpopulation consisted of
previously activated T cells. To address this possibility, we
sorted naive and memory phenotype T cells from untreated,
6-mo-old BALB/c mice. The markers CD44, CD62L, and
CD45RB have all been reported to be useful in discriminating
memory from naive T cells (30–32). Memory T cells express
higher levels of CD44 and lower levels of both CD62L and
CD45RB compared with resting T cells. In Fig. 3, we cul-
tured memory and naive T cells in the presence or absence of
10 ng/ml IL-6 for 30 h. Cell survival was assessed in these as-
says by FITC–annexin V staining as described in Materials and
Methods. Fig. 3 A shows that CD44lowCD45RBhigh (naive) T
cells were rescued from apoptosis by IL-4, IL-2, and IL-6. In
Fig. 3 B the CD44highCD45RBlow (memory) T cells were not
rescued by IL-6, but were rescued by IL-2 and IL-4. When
CD44lowCD62Lhigh (naive) T cells were compared with
CD44highCD62Llow (memory) T cells (Fig. 3, C and D), again
only the naive T cells were rescued from death by IL-6,
whereas IL-2 and IL-4 were capable of rescuing both naive
and memory T cells. These results suggest that it is not just the
activation state of a T cell, but perhaps the activation history of
a T cell, that determines its sensitivity to IL-6 survival signal-
ing. Although we identified a subpopulation of resting T cells
(memory cells) that was unresponsive to IL-6, there was still a
significant population of IL-6–unresponsive T cells in the na-
ive population. Thus, there may be additional factors that can
shut off sensitivity to IL-6. Alternatively, perhaps CD44 and
CD45RB or CD62 levels do not define all memory T cells.
We were interested in determining the mechanism by
which activated T cells lost sensitivity to IL-6 survival sig-
naling. There were three possibilities. The first possibility
was that protein(s) induced after T cell activation interfered
with the IL-6 signaling cascades and thus blocked the abil-
ity of IL-6 to rescue cells from death. A family of intracel-
lular suppressors of cytokine signaling (SOCS) has recently
been described (33–38). Of particular relevance to this pa-
per were the reports demonstrating that SOCS-1 can sup-
press IL-6 signaling in M1 monocytic leukemia cells (34,
35, 37, 38). The second possibility was that the activated T
cells lost expression of IL-6 receptors and were not receiv-
ing IL-6 signals at all. Loss of IL-6 receptor expression on T
cells activated in vitro, or after long-term cell culture, has
been described previously (39, 40). The third possibility
was that IL-6 signaling was intact in the activated T cells
and simply could not interfere with the mechanism that led
to death of the activated cells. Such a hypothesis implies
that activated and resting T cells die by different routes.
We addressed these three hypotheses by measuring
SOCS-1 mRNA levels, IL-6 receptor expression, and IL-6
receptor signaling (Stat phosphorylation) in resting versus
activated T cells.
Analysis of SOCS Expression in Activated versus Resting T
Cells. We attempted to find out whether SOCS-1 played
a role in the suppression of IL-6 signaling in activated T
cells. Fig. 4 shows a reverse transcription (RT)-PCR analy-
sis of SOCS-1 mRNA expression in resting and SEA-acti-
vated T cells. In this experiment, AD10 TCR transgenic
mice were used as a source of T cells. T cells from these
mice all express TCR Vb3 and can therefore be activated
with SEA. Like the B10.BR and C57BL/10 mice, only
resting and not activated T cells from these mice could be
rescued from in vitro death by IL-6 (data not shown). The
AD10 mice were injected with 4 mg SEA; 47 h after injec-
tion total RNA was isolated from spleen and LN T cells,
and cDNA was synthesized as described in Materials and
Methods. We performed RT-PCR for the indicated cycles
Figure 2. Reciprocal effects of IL-6– and IL-2–related cytokines on
resting and activated T cells. LN T cells were isolated from untreated
C57BL/10 mice (A) or from C57BL/10 mice 2 d after intravenous injec-
tion with 150 mg SEB (B). T cells were plated with the indicated
amounts of cytokines at a density of 2 3 105 cells per well in a 96-well
plate. After 36 h in culture, the cells were stained for Vb8.1,2 and ana-
lyzed by PI exclusion for cell death as described in Materials and Meth-
ods. Cells were plated in duplicate wells and the mean of each duplicate is
indicated. This figure shows one of three experiments with similar results.920 Activated and Memory T Cells Have Altered IL-6 Signaling
to compare the levels of SOCS-1 and control hypoxanthine
phosphoribosyltransferase (HPRT) mRNA expression in T
cells from the activated and untreated AD10 mice. Fig. 4
shows that there was not an upregulation of SOCS-1 mRNA
expression in the activated T cells. SOCS-1 was expressed in
both the resting and activated T cells. The amount of
SOCS-1  mRNA by comparison with that of the housekeep-
ing gene, HPRT, was actually slightly higher in the resting
than in the activated T cells. We also found SOCS-2 and
SOCS-3 to be expressed in both populations (data not shown).
The SOCS data did not disprove the idea that there was
active suppression of cytokine signaling, as other SOCS
have recently been described and other mechanisms of cy-
tokine receptor signaling downregulation such as STAT
masking (41, 42) and induction of the protein inhibitor of
activated Stat (PIAS)3 protein (43) have been reported. In-
stead of pursuing other potential mechanisms of inhibition
of receptor signaling, we directly addressed the questions of
whether the IL-6 receptor was expressed on activated T
cells and, if so, whether it was capable of signaling at all.
Downregulation of IL-6 Receptor a Chain after T Cell Acti-
vation.  We used flow cytometry to find out whether loss
of sensitivity to IL-6 survival signals correlated with a loss of
IL-6 receptor. To do this, T cells were isolated from normal
B10.BR mice, or B10.BR mice 2 d after injection of SEA.
The cells were stained with anti-Vb3 or anti-Vb4 antibody
and antibody to the IL-6 receptor a chain. As shown in Fig.
5, the levels of IL-6 receptor a on some of the Vb31 T cells
were reduced by activation but remained normal on by-
stander resting Vb41 T cells. Since resting T cells have a
higher expression of both SOCS-1 and IL-6 receptor than
do the activated T cells we believe the ratio of SOCS-1 to
IL-6 receptor in the two populations to be fairly similar. It
seems unlikely to us that the partial downregulation of IL-6
receptor was fully responsible for the complete insensitivity
of the activated T cells to IL-6. Therefore, we next addressed
the question of whether this level of receptor was capable of
signaling in the activated T cells.
IL-6 Induces Phosphorylation of Stat3 in Both Activated and
Resting T Cells. One of the ways that IL-6 signals is via
phosphorylation and activation of the kinases Janus kinase
(Jak)2 and Tyk2. These kinases in turn phosphorylate Stat3
at Tyr705 (44, 45). To address whether IL-6 signaled in the
activated T cells, we performed phospho-Stat3 Western
blots of lysates from resting and activated T cells. LN T
cells from SEB-treated mice were sorted into resting and
activated populations as described in Materials and Meth-
ods. Like unsorted cultures of cells, these cultures showed
IL-6 rescue only in the resting and not the activated popu-
lations, whereas IL-4 rescued both populations from death
(data not shown). Fig. 6 shows that both activated and rest-
Figure 3. IL-6 rescues naive but not memory T cells
from death in vitro. Splenic T cells were isolated from
untreated BALB/c mice. The cells were sorted into naive
and memory populations as described in Materials and
Methods. The cells were plated at a density of 105 cells
per well in a 96-well plate in the presence of medium
alone, 20 ng/ml IL-4, 20 ng/ml IL-6, or 200 ng/ml IL-2.
Cell death was measured by FITC–annexin V staining af-
ter 30 h in culture. (A) Naive (CD44lowCD45RBhigh)
T cells. (B) Memory (CD44highCD45RBlow) T cells.
(C) Naive (CD44lowCD62Lhigh) T cells. (D) Memory
(CD44highCD62Llow) T cells. The error bars represent
the SD of triplicate wells. This figure represents one of
two experiments with similar results. 
Figure 4. Activated and resting T cells contain approximately the same
amount of SOCS-1 mRNA. AD10 TCR transgenic mice were injected
intraperitoneally with 4 mg SEA, and LN and spleen T cells were isolated
and pooled from either untreated mice or 47-h SEA–treated mice. Total
RNA and cDNA were obtained from 5 3 107 cells as described in Mate-
rials and Methods. RT-PCR was performed with oligos specific for con-
trol HPRT or SOCS-1 for the indicated number of cycles. PCR products
were separated in a 1.5% agarose gel and analyzed for ethidium bromide
intensity using a Nucleovision Imaging Workstation from Nucleotech.921 Teague et al.
ing T cells phosphorylated Stat3 Tyr705 after a 20-min in-
cubation with 10 ng/ml IL-6. Similar levels of total Stat3
were observed in all the lanes after stripping and reprobing
of the same blot (Fig. 6, bottom).
Other signaling cascades, besides the Jaks, can be turned
on after IL-6 receptor binding. Independent of Stat3, Tyr705
phosphorylation by Jak2 and Tyk2 and subsequent transloca-
tion of Stat3 to the nucleus Stat3 can also be phosphorylated
on Ser727. This latter phosphorylation event is believed to be
mediated by a mitogen-activated protein kinase–indepen-
dent serine kinase (46). We show in Fig. 7 that both resting
and activated T cells phosphorylated Stat3 on Ser727 after a
20-min exposure to 100 ng/ml IL-6, and thus this signaling
cascade, like that involved in the tyrosine phosphorylation of
Stat3, was apparently intact in the activated T cells. Fig. 7
(bottom) shows that similar levels of total Stat3 were present
in all the lanes of the blot.
Inhibition of IL-6–induced Stat1 Phosphorylation in Acti-
vated T Cells. Another DNA-binding protein known to
be phosphorylated in response to IL-6 is Stat1 (43, 47–50).
We addressed whether Stat1 signaling was also intact in
the activated T cells by performing anti–phospho Stat1
Western blots. LN T cells from untreated or SEB-treated
mice were sorted into resting and activated populations, as
described in Materials and Methods. Fig. 8 shows the lev-
els of Stat1 phosphorylation and total Stat1 for the acti-
vated and resting T cells after a 20-min exposure to 10 ng/ml
IL-6 or medium alone. There was no phosphorylation
seen in either population in the absence of IL-6 treatment,
but very significant phosphorylation seen in the resting T
cells treated with IL-6. Interestingly, the IL-6–induced
Stat1 phosphorylation in the activated T cells was reduced
to a barely detectable level. This result suggests that there
is active inhibition of IL-6–mediated Stat1 signaling after
T cell activation. Preliminary experiments show that this
reduction in Stat1 phosphorylation after IL-6 exposure is
also true for memory T cells (data not shown).
Since the activated T cells bear lower levels of IL-6 recep-
tor, it was possible that Stat1 phosphorylation was simply de-
layed in response to IL-6 in activated T cells compared with
their resting counterparts. To test this, we examined Stat1
and Stat3 phosphorylation in resting and activated T cells 2 h
after addition of IL-6 (Fig. 9). As before, Stat1 was much less
phosphorylated in activated than resting T cells 20 min after
addition of IL-6. In fact, no phosphorylated Stat1 could be
detected in either type of cell 2 h after addition of IL-6. In
contrast, Stat3 was well phosphorylated in both types of cell
20 min after IL-6 addition.
Figure 5. Activated T cells bear z50% fewer IL-6 re-
ceptors than resting T cells. LN T cells were isolated from
an untreated (A and C) or SEA-treated (B and D) B10.BR
mouse. The mouse was injected with 1 mg of SEA intra-
peritoneally 3 d before harvest of LNs. T cells were stained
with anti-Vb4–FITC, anti-Vb3–FITC, and either anti–
IL-6 receptor a–biotin or control IgG2bk-biotin mAb fol-
lowed by streptavidin-CyChrome as described in Materials
and Methods. The IL-6 receptor a histograms are shown
in white and the control mAb histograms are shown in
black. The values above each histogram represent the me-
dian fluorescence intensities. A and B show the receptor
stains of cells gated on Vb31 T cells; C and D show the re-
ceptor stains of the Vb41 T cells. This is one of nine sepa-
rate experiments that showed downregulation of IL-6 re-
ceptor a after T cell activation.
Figure 6. IL-6 induced phos-
phorylation of Stat3 at Tyr705 in
both activated and resting T
cells. T cells from C57BL/10
LNs were sorted into resting
(Vb4,6,11,14) and activated
(Vb8) as described in Materials
and Methods. Cells were treated
with 10 ng/ml IL-6 or medium
alone for 20 min and lysed. Each lane contains 2.5 3 106 cell equivalents.
The top panels show the anti–phospho-Stat3 (Tyr705) blot (P-Tyr Stat3).
The bottom panels show the total Stat3 in each lane after stripping and
reprobing. This is one of three experiments with similar results.
Figure 7. IL-6 induced phos-
phorylation of Stat3 at Ser727 in
both activated and resting T cells.
T cells from C57BL/10 LNs
were sorted into resting (Vb5)
and activated (Vb8) as described
in Materials and Methods. Cells
were treated with 100 ng/ml IL-6
or medium alone for 20 min and
lysed. Each lane contains 6 3 105
cell equivalents. The top show
the anti–phospho-Stat3 (Ser727) blot (P-Ser Stat3). The bottom panels show
the total Stat3 in each lane after stripping and reprobing. This is one of
three experiments with similar results.922 Activated and Memory T Cells Have Altered IL-6 Signaling
Discussion
The fact that T cells die in vitro at a much faster rate
than in vivo suggests that there are survival factors in vivo
that are absent in standard tissue culture medium. Several
extracellular and intracellular factors have been identified
that are capable of blocking or delaying apoptosis of T cells
in vitro (16, 17, 19, 23, 25, 51–53). Engagement of CD28
or any one of multiple cytokines can prevent or delay the
death of T cells after activation. Several cytokines have also
been reported to prolong survival of resting T cells in vitro.
Although sufficient for survival in vitro, it is still unclear
whether any of these factors are necessary for the survival
of activated or resting T cells in vivo. It is likely that in vivo
a T cell integrates multiple survival and death signals in its
decision to proliferate, differentiate, survive, or die.
We previously showed that T cells activated in the pres-
ence of a proinflammatory environment induced by LPS
were protected from deletion (18). Although the LPS effect
on the activated T cells was indirectly mediated by the
proinflammatory cytokines IL-1a and TNF-a it was unclear
whether the direct mediators of T cell survival were soluble
or cell bound in this system. We previously reported that IL-6
produced by endothelial cells was a survival factor for resting
T cells (16). Since IL-6 is a proinflammatory cytokine, we
were interested in its effects on activated T cells. We show in
this paper that IL-6 could rescue only naive resting T cells
and was ineffective at promoting survival of activated T cells
or T cells bearing memory markers. Thus, the IL-6 effect is
unlike the effect of the IL-2 family of cytokines (IL-2, IL-4,
IL-7, and IL-15), which does rescue activated T cells (19,
51) and memory T cells (Fig. 3).
It is possible that these effects of IL-6 were not due to
direct action of IL-6 on resting T cells, but rather due to
induction by IL-6 of another molecule that itself was re-
sponsible for the differential survival of resting versus acti-
vated T cells. However, we do not think this is the case for
several reasons. First, the IL-6 helped purified resting T
cells survive. Therefore, if the effects of IL-6 were mediated
by a second molecule, this would have had to be induced by
IL-6 on resting T cells. Second, as shown earlier and discussed
below, survival of resting versus activated T cells was accom-
panied by differential phosphorylation of Stat1, a signal trans-
duction protein known to be affected by the IL-6 receptor.
Third, one of the best-characterized factors induced by IL-6
is IL-4 (39). Although IL-4 is a survival factor for resting T
cells, it also, unlike IL-6, acts as such for activated T cells.
Moreover, we have shown that IL-6 is a survival factor for
resting T cells from IL-4 knockout mice. Therefore, we do
not believe the effects of IL-6 reported here are secondary to
induction by IL-6 of some other factor.
We addressed whether the loss of sensitivity to IL-6 was
restricted to the T cells that engaged antigen. We found
that bystander resting T cells, isolated from the same mouse
as the activated T cells, were rescued by IL-6. These data
strongly suggested that engagement of the TCR was re-
quired for the mechanism driving the IL-6 insensitivity,
and that cytokines or upregulated adhesion molecules after
T cell activation in the mouse were insufficient to promote
the IL-6 insensitivity.
A lot is known about signaling via the IL-6 receptor. The
binding of the IL-6 receptor a chain to IL-6 initiates associa-
tion with gp130 (the IL-6 receptor signaling subunit) to
form an IL-6–specific signaling complex on the cell surface.
After homodimerization and phosphorylation of gp130,
there is recruitment and activation of several kinases that in
turn phosphorylate and activate DNA binding proteins such
as the Stats (47, 54). IL-6 signaling is known to be mediated
by the tyrosine kinases Jak1, Jak2, and Tyk2, as well as serine
kinases (45, 47, 55). The activation of these kinases leads to
phosphorylation of Stat1 on Tyr701 (47–50, 56) and phos-
phorylation of Stat3 on both Tyr705 and Ser727 (46, 55–58).
Immediately after phosphorylation, the Stat proteins form
either homodimers or heterodimers and translocate to the
nucleus where they bind DNA and drive transcription (47).
Inhibition of IL-6 receptor signaling at any step before phos-
phorylation of either Stat1 or Stat3 could result in the inhibi-
tion of all or some of the IL-6 effects on a cell.
With this information in mind, we tested whether IL-6
fails to prevent the death of activated T cells because of a
defect in its signaling pathway in these cells. Activated T
cells bore about half the number of IL-6 receptors per cell
than resting T cells. However, we do not think this was re-
Figure 8. IL-6–induced phosphorylation of Stat1 at Tyr701 was inhib-
ited in the activated T cells by comparison with resting T cells. T cells
from C57BL/10 LNs were sorted into resting and activated populations
as described in Materials and Methods. Cells were treated with 10 ng/ml
IL-6 or medium alone for 20 min and lysed. Each lane contains 2 3 106
cell equivalents. The top panels show the anti–phospho-Stat1(Tyr701) blot
(P-Tyr Stat1). The bottom panels show the total Stat1 in each lane after
stripping and reprobing. The arrows indicate the larger and smaller forms
of Stat1 that are recognized by these antibodies. This is one of three ex-
periments with similar results.
Figure 9. Activation of T cells does not lead to delayed Stat1 (Tyr701)
phosphorylation. Resting (Rest) and activated (Act) T cells were prepared
and analyzed as described in the legends to Figs. 7 and 8 except that the
cells were harvested after 20 min or 2 h incubation in IL-6.923 Teague et al.
sponsible for the failure of IL-6 to rescue activated cells be-
cause IL-6 binding induced the phosphorylation of Stat3
on both Tyr 705 and Ser727 in both activated and resting T
cells. Thus, the receptor on activated cells could deliver
signals effectively.
Notably, engagement of IL-6 failed to induce phosphor-
ylation of Stat1 tyrosines in activated T cells, whereas this
phosphorylation occurred efficiently in resting T cells. This
failure was not due to loss of Stat1 protein, and was thus
caused by a real difference in signaling via the IL-6 recep-
tor in activated T cells. The loss of Stat1 phosphorylation
would prevent the transcription of genes that require Stat1
homodimer or Stat1/Stat3 heterodimer binding, but leave
genes induced by Stat3 alone or in combination with other
binding proteins intact. Thus, Stat1-induced genes are prob-
ably required for IL-6–mediated T cell survival. It is inter-
esting to consider this result in light of our recent finding
that type 1 IFNs slow the rates of death of activated but not
resting T cells (59). As type 1 IFNs also induce Stat1 phos-
phorylation, perhaps T cell death can be slowed by some
combination of signaling by Stat1 and another, unknown
factor(s) which is induced in resting T cells by IL-6 and in
activated T cells by type 1 IFNs.
Mechanisms of IL-6 receptor signaling downregulation
such as Stat masking (41, 42), induction of the PIAS1 (60)
and PIAS3 proteins (46), and the SOCS family of Jak bind-
ers (33–38) have been recently described. The Stat masking
and PIAS mechanisms of inhibition do not prevent the
phosphorylation of Stats, whereas the SOCS inhibitors do.
SOCS-1 has been reported to be an effective inhibitor of
IL-6–induced Stat phosphorylation in a myeloid leukemia
cell line and was shown to be upregulated by several cyto-
kines (35, 37, 38). We are interested in determining whether
SOCS-1 induction after T cell activation was responsible
for the lack of IL-6–mediated survival or Stat1 phosphory-
lation in the activated T cells.
We did not find an induction of SOCS-1 mRNA after T
cell activation. SOCS-1 was expressed in the T cells even
before activation and could not be ruled out as a potential
mediator of the insensitivity to IL-6 signaling found in many
of the resting T cells. It is also possible that the functional
regulation of these SOCS proteins is posttranscriptional or
posttranslational. Currently, we are investigating the possibil-
ity that a SOCS-like inhibitor is recruited to one of the IL-6
receptor–associated Jaks after T cell activation. The selective
inhibition of Stat1 signaling in the activated cells may be due
to a lack of activation or recruitment of some but not all of
the Jaks normally associated with gp130. This type of inhibi-
tion would allow recruitment and activation of some Stat
proteins but not others.
In sum, these results suggest that some aspects of the IL-6
receptor are unaffected by T cell activation, whereas at least
one signaling pathway is lost. This suggests that T cell activa-
tion leaves the T cells able to go through some, but not all,
of the differentiative processes associated with IL-6. This is
consistent with previous reports showing that IL-6 can in-
duce differentiation of activated CD81 T cells into cytotoxic
T cells (61–64), can promote activated CD41 cell differenti-
ation to the Th2 phenotype (39), and with the data shown
here, cannot promote the survival of activated T cells.
A probable teleological reason for the lack of IL-6 rescue
of activated cells is to provide selective protection of non-
specific T cells during antigen-driven cell death in vivo.
Many activated T cells die during immune responses to an-
tigen, perhaps to avoid accumulation of once useful but
now functionless cells, or to prevent shock during a second
exposure to the same antigen. Insensitivity to IL-6 may
contribute to the loss of activated cells, as their death
would not be prevented by this cytokine. Naive T cells
may depend on IL-6 for maintenance of survival in specific
environments in vivo such as spleen, LNs, or during travel
through the circulatory system. Many cell types, such as
endothelial cells and fibroblasts, constitutively secrete low
levels of IL-6, thus providing resting T cells with plenty of
opportunities to engage IL-6 (16, 65–68).
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